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Epidemiology of Arrhythmias 
Arrhythmias are one of the major healthcare challenges since they are very common affecting 
millions of Europeans1-4 and are associated with significant morbidity and mortality since they 
are the main cause for sudden cardiac death5, 6. 
Various arrhythmias exist, ranging from less harmful premature extra beats to life-threatening 
heart block, from inherited preexcitation syndromes in children to acquired post-infarction 
ventricular fibrillation in aged patients, and from rare familial arrhythmia syndromes to the 
most common arrhythmia, atrial fibrillation (AF). Epidemiology data demonstrate an overall 
prevalence of arrhythmias of 3,4% (ranging from 1,4% in patients younger than 18 years to 
10,1% in patients older than 75 years)5. Thus, arrhythmias affect many patients at all ages with 
or without concomitant heart disease and represent a major public health burden. 
Arrhythmias are the main reason for sudden cardiac death that account for 25% of all deaths7-
10 and are associated with significant morbidity such as a five-fold increased stroke risk, a 
doubling in dementia risk, and a tripling in heart failure risk2, 6. Improved treatment options in 
cardiology such as coronary interventions in patients with myocardial infarction or 
implantable defibrillators in patients with heart failure have led to survival of previously fatal 
diseases but have also led to increased numbers of acquired arrhythmias. Thus, the overall 
incidence of arrhythmias is rising and accounts for an increasing proportion of hospitalizations 
and healthcare costs11-13. 
 
Current treatment options 
Therapy depends on the specific arrhythmia and includes drug therapy, catheter ablation, 
device implantation as well as treatment of concomitant diseases5, 14. Pharmacotherapy using 
betablockers or antiarrhythmic drugs such as ion channel blockers are used to control heart 
rate, to suppress premature extra beats, to slow down electrical conduction through the AV 
node in case of atrial tachycardias, to convert arrhythmias to sinus rhythm, or to stabilize sinus 
rhythm15-19. Oral anticoagulation is further necessary to prevent thromboembolic events such 
as strokes in AF20, 21. In recent years, interventional catheter-based therapies were 
developed22, 23. Ablation of accessory muscle bundles can cure several forms of re-entrant 
tachycardias24, 25, pulmonary vein isolation (PVI) 22, 23 became a standard treatment for AF, and 
ablation of ventricular tachycardia is performed to prevent life-threatening arrhythmias26, 27. 
More than 50 years ago cardiac pacemakers were developed that allowed to treat life-
threatening bradycardia such as sinus arrest. Furthermore, implantable cardioverter-
defibrillators (ICD) have been developed to terminate ventricular tachyarrhythmias. This is of 
special interest for patients with increased risk for lethal arrhythmias, e.g. patients with 
arrhythmia syndromes such as Long QT Syndrome and for patients with reduced left 
ventricular function after myocardial infarction. In those patients ICD implantation has been 
demonstrated to allow prevention of sudden cardiac death28, 29. 
Those innovative treatment options have substantially improved survival but remain 
ineffective in a number of patients, remain largely symptomatic therapies without targeting 
the causal factors and are associated with numerous complications30, 31 and side effects32. 
Preventing tachyarrhythmias with betablockers might result in bradycardia and syncope, oral 
anticoagulants for stroke prevention might result in major bleedings32, and implanted devices 
might cause lead infection, heart failure due to permanent ventricular stimulation, or 
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repetitive hospitalisations due to inadequate ICD therapies33, 34. Therefore, current treatment 




The pathophysiologic basis of arrhythmias is complex (Fig.1) and still incompletely understood 
but similarities of fundamental mechanisms between different forms of arrhythmias have 
been identified35-37. In general, arrhythmias occur either due to impaired impulse formation 
and/or impulse propagation. Physiologically, generation and propagation of electrical 
impulses in the heart is achieved by a characteristic sequence of voltage changes implemented 
by depolarizing and repolarizing ion currents. The normal resting membrane potential of 
cardiomyocytes is around -80 mV. An electrical impulse causes a depolarization by rapidly 
activated sodium channels with following influx of sodium ions. Subsequently, potassium 
channels open initiating the repolarization of the cell (re-establishing the resting membrane 
potential again). Simultaneously, calcium ions enter the cell leading to cell contraction 
(excitation-contraction-coupling) and slowing of the repolarization. 
In the healthy heart, the sinus node expresses specific ion channels (funny channels) that are 
responsible for the so-called automaticity (i.e. the progressive diastolic depolarization) and 
dominates the impulse generation. An upregulation of these ion channels, as seen in heart 
failure, could be a possible mechanism leading to enhanced automaticity38. Furthermore, it is 
possible that a cell outside the sinus node reaches the threshold potential earlier resulting in 
ectopic firing at a more rapid rate potentially leading to atrial tachycardia. In this regard, 
alterations of the cellular calcium homeostasis may play an important role as it has been 
demonstrated in animal models and patients37. Physiologically, cellular calcium is removed by 
the Ca2+-ATPase (SERCA) and the Na+-Ca2+-exchanger (NCX) during diastole to re-establish 
ionic homeostasis at the end of the cardiac cycle. During atrial tachycardia, however, calcium 
is progressively accumulated in the cell because of repetitive activation of the L-Type Ca2+ 
channel resulting in a calcium overload that in turn leads to multiple maladaptive changes 
such as impairment of the ryanodine receptor (calcium release channel in the sarcoplasmatic 
reticulum) with subsequent calcium leak from the sarcoplasmatic reticulum and activation of 
NCX causing a depolarizing current leading to so-called delayed afterdepolarizations (DAD). 
This leads to a progressive depolarization of the cell and ectopic firing (when the threshold 
potential is reached; so-called triggered activity)36, 39, 40. Early afterdepolarizations (EAD) occur 
when the action potential duration (APD) is excessively prolonged, for example in the context 
of arrhythmia syndromes such as Long QT syndrome41, 42. 
Another hallmark in arrhythmogenesis is reentry that can occur when altered electrical 
properties cause a shortening of the refractory period or conduction slowing and when 
structural changes (e.g. fibrosis) establish an anatomical substrate37. In the healthy heart, 
reentry cannot occur because cardiomyocytes display a certain refractory period that prevents 
premature stimuli to conduct. When the refractory period is shortened, however, the cell is 
excitable earlier, ectopic activity can be conducted, and reentry can be initiated. Additionally, 
slowed conduction velocity can also allow reentry because cells are excitable again when the 
impulse arrives. Structural changes as dilatation and fibrosis extend conduction pathways, 




Besides these fundamental mechanisms several other factors may lead to arrhythmias, all of 
them are summarized under the term “proarrhythmic atrial remodeling” with mechanisms 
leading to altered ion currents (e.g. enhanced automaticity) categorized as “electrical 
remodeling” and mechanisms leading to anatomic changes (e.g. atrial fibrosis) categorized as 
“structural remodeling” (Fig.1). 
Interestingly, some of the electro-anatomical changes implicated in arrhythmia 
pathophysiology initially act as a protective mechanism of the cell, but finally result in a fixed 
substrate for arrhythmia maintenance. For example, atrial tachycardia (as seen in AF) causes 
a cellular calcium overload. In order to reduce the calcium influx and to antagonize the calcium 
overload the calcium current is reduced (by inactivation of calcium channels (short-term 
effect) and reduced gene expression of the calcium channels (long-term effects)) leading to a 
shortening of the action potential. This favors reentry and therefore contributes to AF 







MicroRNA mediated atrial remodeling 
In 1993 microRNAs (miRNAs) have been discovered as important developmental mediators in 
Caenorhabditis elegans as they regulate gene expression45, 46. Since then, thousands of 
miRNAs, which are short (i.e. 20-22 base pairs), single-stranded, non-coding RNA fragments, 
have been identified in other animals and plants playing key roles in various physiologic and 
pathophysiologic conditions. MiRNA binding to the 3‘ untranslated region (3’ UTR) of a target 
mRNA results in post-transcriptional inhibition of gene expression by repression of the 
translation or the degradation of the target mRNA47, 48. Thus, miRNAs can both cause 
downregulation of genes (by direct binding to target mRNAs) but also (indirect) upregulation 
of genes (by binding and downregulation of intrinsic inhibitors of these genes). Since miRNAs 
can bind to various target genes and one gene can be targeted by various miRNAs a complex 
regulatory network with up- and downregulation of agonists and antagonists at the same time 
is established leading to the concept of miRNAs as „fine tuners“ of gene expression49. Over 
the last years, several miRNAs have been demonstrated as key regulators in cardiac 
development and cardiovascular disease leading to a growing number of studies evaluating 
the role of miRNAs in proarrhythmic remodeling as well37, 50. By targeting genes encoding ion 
channels, connexins, or calcium handling-related proteins miRNAs such as miR-1, -26, -106b-
25, -133, -208, -328, or -499 are mediating electrical remodeling whereas miR-21, -26, -29b, -
30, -499, -590 are mediating structural remodeling by regulating extracellular matrix turnover 
and profibrotic signaling51. 
In a canine ventricular tachypacing model (VTP, 240 bpm) that has previously established as 
model for AF in the context of congestive heart failure52, 53, we studied the role of miR-29b in 
regulating proarrhythmic remodeling54. Already 24 hours after initiation of VTP miR-29b was 
significantly downregulated (Fig.2A) abolishing its inhibitory effects on the expression of 
several extracellular matrix genes such as collagens (COL1A1, COL3A1) and fibrillin (FBN1) that 
were upregulated 2 weeks later (Fig.2D-F) when significant atrial fibrosis and increased 
vulnerability for AF were also present (Fig.2B-C). To confirm the causal effects of miR-29b on 
matrix gene expression we isolated fibroblasts from the left atrium and infected these cells 
with a lentivirus containing the miR-29b precursor sequence or a complementary target 
sequence (a so-called miR-sponge) to induce a miR-29b overexpression or knockdown, 
respectively. Upregulation of miR-29b in these cells resulted in significantly reduced 
expression of COL1A1, COL3A1, and FBN1 whereas a downregulation of miR-29b showed the 
opposite effect (Fig.2G-H). In sum, these data suggest a causal role for miR-29b in regulating 






In a next step we studied the expression of miR-29b in human heart tissue obtained from 
patients who underwent cardiac surgery. We could show that the expression of miR-29b in 






The extent of atrial fibrosis is associated with the outcome after AF therapy, but measurement 
of atrial fibrosis in vivo remains challenging since the gold standard for fibrosis quantification 
is still histology which requires the staining of tissue samples obtained from the individual 
patient55, 56. Innovative attempts using MRI scans are promising but still experimental and not 
available in clinical routine. Since miRNAs such as miR-29b regulate structural remodeling and 
are expressed in the human heart as well (Fig.3A), we studied the expression of miRNAs in 
human blood samples to evaluate their role as potential biomarkers for atrial fibrosis. 
However, it was not known how blood samples have to be processed to allow reliable 
measurement of miRNAs. To test this and to establish preanalytical quality criteria we 
measured miR-21 and miR-1 expression in blood samples under various conditions57. We 
collected blood samples in different collection tubes containing ETDA, heparin or serum 
separator, processed samples immediately to plasma/serum, isolated RNA and measured 
miRNA levels. We could show that miRNA measurement can be achieved from blood samples 
collected both in EDTA plasma and serum tubes whereas miRNAs were undetectable upon 
contact to heparin (Fig.4A). We then applied repetitive freeze-thaw cycles to plasma and 
serum samples and observed a decrease in miR-21 both in plasma (∆CT values: 5.59±0.19 vs. 
6.38±0.21, p<0.05) and serum (∆CT values: 4.45±0.75 vs. 8.74±0.88, p<0.01) and a decrease 
in miR-1 levels in plasma (∆CT values: 15.57±0.69 vs. 16.31±0.62, p<0.05) after 4 freeze-thaw 
cycles (Fig.4B-C). In daily practice it might not be possible to immediately process blood 
samples, thus, we mimicked this situation by incubating the samples at room temperature for 
24 hours and 4 days before (full blood samples) and after processing (plasma/serum samples). 
In full blood samples collected into EDTA containing tubes miRNAs were stable for after 4 days 
whereas in serum separator containing tubes miR-21 levels were significantly reduced after 4 
days (∆CT values: 4.5±0.75 vs. 8.5±0.64, p<0.01, Fig.4D-E). In processed plasma/serum 
samples, however, both miR-21 (∆CT values in plasma: 5.60±0.19 vs. 7.65±0.68, p<0.05; ∆CT 
values in serum: 4.45±0.75 vs. 7.97±0.65, p<0.01) and miR-1 (∆CT values in plasma: 15.6±0.69 
vs. 18.7±0.83, p<0.001; ∆CT values in serum: 15.72±1.02 vs. 18.29±0.40, p<0.05) were 
significantly reduced already after 24 hours (Fig.4F-G). To evaluate the effect of physical 




and after processing (plasma/serum) on a shaker for one and eight hours. We showed that 
one hour of shaking did not affect miRNA levels in any of the sample types, after eight hours 
of shaking, however, miR-1 levels in full blood collected in serum tubes (15.72±1.02 vs. 
17.50±0.31, p<0.05) and in plasma (15.57±0.69 vs. 18.77±0.81, p<0.01) as well as miR-21 levels 





According to these preanalytical considerations we measured the expression of miR-29b in 
human plasma samples (Fig.3B)54. We could show that miR-29b is significantly reduced in 
plasma obtained from patients with AF (8.96±2.67 vs. 19.54±1.97, p<0.001), from patients 
with heart failure without AF (5.82±0.88 vs. 19.54±1.97, p<0.001) and from patients with AF 
and concomitant heart failure (10.03±1.25 vs. 19.54±1.97, p<0.001) compared to patients 
without heart disease. A multivariate regression analysis showed that miR-29b plasma levels 
remained significantly reduced in all groups after adjusting for age, sex, cardiovascular risk 
factors (hypertension, diabetes mellitus, hypercholesterolemia), concomitant coronary artery 
disease, or drug treatment (treatment with ACE inhibitors/AT1 blockers, aldosterone 
antagonists, statins) suggesting a potential role for circulating miR-29b as biomarker for 
proarrhythmic remodeling. 
Heart diseases such as congestive heart failure are an important predisposing factor for 
arrhythmias as they induce proarrhythmic remodeling58. However, even without underlying 
heart diseases arrhythmias can occur59-61. In recent years, a growing body of evidence suggests 
that genetics may be an important factor responsible for developing arrhythmias62-65. 
Genome-wide association studies (GWAS) revealed significant associations between genetic 
variants and an increased risk for AF66, 67 and other arrhythmias68-71. However, the underlying 
mechanisms how these variants may cause arrhythmias are unknown in most cases especially 
since these risk variants are often located in „genomic deserts“ without any known gene. To 
further evaluate if altered miRNA signaling could be the mechanistic link to genetically 
increased AF risk we studied the gene SHOX2, a transcription factor with an essential role in 
cardiac development, especially of the sinus node72. Since sinus node dysfunction is associated 
with AF73, SHOX2 is a plausible candidate gene to study genetic susceptibility. We measured 
expression of SHOX2 in right atrial tissue and could show that SHOX2 expression is significantly 
reduced in patients with AF compared to patients in sinus rhythm (Fig.5A). We then performed 
SHOX2 sequencing in 378 patients with early-onset AF (i.e. before the age of 60 years) and 
identified a genetic variant within the 3‘ untranslated region of the SHOX2 gene (c.*28T>C) 
that was significantly associated with AF (p<0.01). AF Patients with this genetic variant show 
a prolonged PR interval during sinus rhythm which is a surrogate parameter for altered atrial 
conduction properties indicating a functional effect of this genetic variant (Fig.5B). Since 
miRNAs regulate gene expression by binding to target sequences in non-coding regions we 
hypothesized that this variant generates a novel miRNA binding site and thus affects 
arrhythmogenesis. Indeed, we could demonstrate that this genetic variant cause a novel 
binding site for miR-92b-5p which may explain the reduced SHOX2 expression in the atria of 
AF patients. This is further supported by the finding that miR-92b-5p plasma levels were 
similar in patients with or without AF (Fig.5C) but were significantly reduced in patients 
carrying the variant (Fig.5D) suggesting a miR-92b-5p enrichment in the heart in patients 
carrying the genetic variant. In sum, our data suggest that miRNA-mediated remodeling may 






An individual‘s lifestyle is – besides genetic factors – an important risk factor for the 
development of arrhythmias, especially in otherwise healthy people such as athletes74-76. The 
underlying mechanisms however, are incompletely understood but miRNA-mediated 
remodeling may play an important role77. To study the potential effects of miRNAs in athletes 
we measured circulating miRNAs in healthy people participating in a marathon78. We recruited 
15 runners who performed intense physical training throughout the year (“elite runners”) and 
15 runners who performed only seasonal training (“non-elite runners”). We collected blood 
at different time points (before and after a 10 week training period before the marathon, 
immediately and 24 hours after the marathon) and correlated miRNA expression levels with 
echocardiographic parameters for remodeling. We focused on 5 miRNAs that have previously 
been demonstrated as mediators of cardiac remodeling51: miR-1, miR-133a, miR-30a, miR-
26a, and miR-29b. In both groups, expression of all 5 miRNAs was similar over time (Fig.6A-E). 
After the marathon miR-1, miR-133a and miR-30a increased (significant increases of miR-30a 
in both groups and miR-1/-133a in elite runners) whereas miR-26a and miR-29b decreased 
(significant decrease of miR-26a in elite runners). In non-elite runners we could not identify 
correlations between miRNA levels and echocardiographic parameters, while in elite runners 




correlated with LA diameter, a surrogate parameter for structural remodeling (Fig. 6F-G). In 
our study, alterations in miRNA plasma levels are pronounced and correlate with LA diameter 
only in elite runners with regular and more intense training suggesting that i) miRNAs might 
be involved in proarrhythmic remodeling in athletes, and ii) that circulating miRNAs could 







Macrophage mediated atrial remodeling 
Macrophages are important cells of the innate immune system which identify and eliminate 
pathogens by phagocytosis and release cytokines and chemokines to recruit further immune 
cells to the site of inflammation79. Besides their role in host defense against infectious 
pathogens macrophages have also been demonstrated to play important regulatory roles in 
the context of sterile inflammation as seen in many chronic diseases such as diabetes 
mellitus80-83. 
Diabetes mellitus is associated with an increased risk for arrhythmias, but the underlying 
mechanisms are unknown so far84-87. Recently, a study using a mouse model of diabetes 
suggests an inflammatory mechanism and a role for macrophages88. In this model 
macrophages are recruited to the heart where they release the cytokine IL-1β which mediates 
an electrical remodeling resulting in reduced potassium currents, altered calcium 
homeostasis, prolonged QT interval and action potential duration, and increased susceptibility 
for arrhythmias. 
Recent studies suggest that inflammatory mechanisms are also involved in the 
pathophysiology of arrhythmias such as AF even in the absence of overt chronic inflammatory 
diseases89, 90. We hypothesized that macrophages are involved in the pathogenesis of AF but 
due to the very limited availability of human heart tissue samples it was not possible to directly 
study macrophages in the heart of patients with AF. Thus, we studied the monocyte 
chemoattractant protein-1 (MCP-1) that has been demonstrated to attract macrophages to 
the site of an inflammation82, 91. Thus, we measured MCP-1 in the blood of patients with AF as 
an indirect marker for macrophage recruitment92. We measured MCP-1 plasma levels in 96 
patients with AF and in 40 patients without AF and observed significantly elevated levels of 
MCP-1 in AF patients (268 pg/ml vs. 227 pg/ml; p=0.03; Fig.7A). Since the patient cohort was 
adjusted for age, sex, type of AF, cardiovascular risk factors, echocardiographic parameters, 
as well as concomitant coronary artery disease, renal failure or antiarrhythmic drug therapy, 
an elevated MCP-1 plasma level indicates a pro-inflammatory condition in AF. To study 
whether MCP-1 plasma levels are directly associated with the heart rhythm or indirectly with 
the degree of atrial remodeling we studied MCP-1 plasma levels before and three months 
after pulmonary vein isolation (PVI). We revealed that MCP-1 levels significantly increased 
after PVI both in patients with stable sinus rhythm (268 pg/ml vs. 349 pg/ml, baseline vs. 3 
months after PVI; p<0.01; Fig.7B-C) and in patients with AF recurrence (281 pg/ml vs. 355 
pg/ml, baseline vs. 3 months after PVI; p=0.03; Fig.7B-C). These data suggest that MCP-1 levels 
i) are not associated with the current heart rhythm (no difference between sinus rhythm vs. 
AF post PVI), ii) might rather indicate a preexistent atrial remodeling and does therefore not 
allow to predict short-term ablation success (no difference at baseline), and iii) might be 
associated with a PVI-induced pro-inflammatory and pro-fibrotic response potentially 
indicating scar formation after ablation. In sum, these data provide evidence that MCP-1 is 
altered in patients with AF indicating that a macrophage-related inflammatory mechanism 






Over the recent years several macrophage subsets have been demonstrated, most 
importantly “inflammatory macrophages” originating from circulating monocytes that are 
recruited to sites of inflammation and “resident macrophages” which are located within 
different organs during steady-state, i.e. without any inflammation mediating tissue 
homeostasis79, 93, 94. Although resident macrophages have been described in the healthy heart 
as well, their spatial distribution and their specific function was unknown. 
In a genetically modified mouse model where macrophages are fluorescently labeled 
(Cx3cr1GFP/+) we could demonstrate that resident cardiac macrophages are enriched within the 
AV node by flow cytometry and histology (Fig.8)95. We then performed optical clearing and 
confocal microscopy imaging of AV nodes and revealed that resident macrophages frequently 






Since cardiomyocytes are functionally connected with adjacent cells by gap junctions formed 
by connexins we isolated AV node macrophages by fluorescent-activated cell sorting (FACS) 
and determined expression of connexins (Fig.9A). We found that AV node macrophages 
mainly express Connexin-43 (Cx43) establishing on average three contact points between 
macrophages and cardiomyocytes indicating gap junctions (Fig.9B). Since gap junctions allow 
electrical conduction between neighboring cardiomyocytes, we therefore hypothesized that 
macrophages are electrotonically coupled to cardiomyocytes via gap junctions as well. 
To test this we co-cultured FACS-purified AV nodal macrophages and neonatal cardiomyocytes 
and confirmed Cx43-positive contact points indicating gap junctions between macrophages 
and cardiomyocytes (Fig.9C). Whole-cell patch-clamp experiments (Fig.9D-E) revealed typical 
resting membrane potentials and action potentials in cardiomyocytes (Fig.9F). In isolated 




cardiomyocytes) and we did not observe spontaneous electrical activity (Fig.9G). After three 
days of co-culture of neonatal cardiomyocytes with isolated macrophages, however, we found 
rhythmic depolarizations in 23% and irregular electrical activity in another 23% of the 
macrophages connected to cardiomyocytes (Fig.9H). The resting membrane potential of these 
macrophages was hyperpolarized compared to solitary macrophages indicating electrical 
coupling. To further study the interaction between both cell types we measured resting 
membrane potentials in cardiomyocytes coupled to macrophages and could demonstrate that 
these cardiomyocytes are more depolarized (compared to solitary cardiomyocytes) and that 
treatment of co-cultured cells with a Cx34 inhibitor could reverse this effect while treatment 











Next, we used the data from patch clamp experiments to perform a mathematical modeling 
of electrical interactions between macrophages and cardiomyocytes (Fig.10). According to this 
modeling macrophage coupling depolarizes the resting membrane potential and shortens the 
action potential duration of the coupled cardiomyocyte, effects that are further enhanced if 
more macrophages are coupled to the cardiomyocyte. These data indicate that macrophage 
coupling may enhance electrical conduction since an increased resting membrane potential 
allows to easier/faster reach the depolarization threshold and a shortened action potential 




To test this directly in the AV node we generated a transgenic mouse model expressing a 
photoactivatable channelrhodopsin 2 (ChR2) specifically in macrophages. ChR2 is a cation 
channel that opens upon stimulation by light and allows influx of sodium ions, i.e. a 
depolarization of the cell. Hearts from these mice (Cx3cr1 ChR2) were then perfused using a 
Langendorff apparatus and the RV free wall was removed to expose the AV node allowing to 
specifically illuminate the AV node (Fig.11A-D). To study the electrical conduction through the 
AV node we performed atrial pacing to assess the Wenckebach point, i.e. the cycle length at 
which an electrical impulse from the atrium is no longer conducted to the ventricles. When 
we turned on the light illuminating the AV node at the Wenckebach cycle length we observed 
a significantly increased number of stimuli that were conducted indicating an enhanced 







To further confirm the electrophysiology-modulating role of cardiac macrophages we studied 
several mouse models. First, we generated a transgenic mouse model with macrophage-




electrophysiology (EP) studies in these mice revealed prolongation of the PR and AH intervals, 
the AV node refractory periods, the Wenckebach cycle length and the retrograde VA 
conduction cycle length demonstrating an impaired AV conduction (Fig.12B-E). Since the 
number of AV node macrophages was not altered in Cx3cr1 Cx43-/- mice these findings indicate 
that macrophages facilitate electrical conduction in the AV node via Cx43. Next, we performed 
in vivo EP studies in Csf1op mice that congenitally lack macrophages and could confirm the 
findings mentioned above: absence of macrophages in these mice resulted in prolongation of 





Finally, we studied CD11bDTR mice that allow depletion of CD11b-positive cells (including 
resident cardiac macrophages) upon treatment with diphtheria toxin (DT; Fig.13). We 




day after DT injection all mice developed first degree AV block (Fig.13C, E) that progressively 
evolved to second- and finally to third-degree AV block (Fig.13F-G) at the time of maximal 
macrophage depletion about three days after DT injection (Fig.13B). DT injection into C57BL6 
control mice did not alter the ECG excluding toxic effects of DT, parabiosis experiments with 
Cx3cr1GFP/+ mice joined to CD11bDTR mice excluded circulating factors since only in CD11bDTR 
and not in Cx3cr1GFP/+ mice DT injection resulted in AV block, histologic assessment excluded 
apoptosis and fibrosis, blood chemistry tests excluded electrolyte disturbances, and treatment 
with isoproterenol, epinephrine or atropine excluded autonomic regulation as causal factors 
for altered AV conduction. In sum, these in vivo studies suggest that resident cardiac 







Summary and future perspectives 
Arrhythmias are among the most common diseases and are clinically highly relevant since they 
account for significant morbidity and mortality. Over the last decades arrhythmia 
management has been improved, but preventive strategies, diagnostic approaches and 
therapeutic options are still limited and require the development of innovative concepts in 
the future. 
The main reason for this currently still insufficient clinical management of arrhythmias is the 
complex underlying pathophysiology that is still not fully understood despite numerous 
advances that have been made in recent years. In this Habilitation some novel insights into 
cellular and molecular mechanisms leading to proarrhythmic remodeling and 
arrhythmogenesis have been gained. Studies on microRNAs revealed an important role for 
miR-29b in mediating atrial fibrosis in a dog model of heart failure induced AF and altered 
expression in human cardiac tissue suggested a role for miR-29b in humans as well. 
Furthermore, miRNAs circulating in the blood have been evaluated as potential biomarkers 
suggesting a role for miR-29b in profibrotic remodeling in AF patients and for miR-1 and miR-
133a in exercise-induced remodeling in athletes. Additionally, our study on SHOX2 provided 
evidence for novel miRNA binding sites generated by genetic variants, thus, suggesting a 
potential mechanistic link how genetic variants might cause an increased risk for arrhythmias. 
In addition to miRNA mediated mechanisms the role of immune cells, especially macrophages 
in arrhythmogenesis has been investigated. Our study on circulating MCP-1 revealed that 
MCP-1 levels are increased in AF patients and are further increasing after pulmonary vein 
isolation pointing towards immunologic mechanisms. Most importantly, cardiac resident 
macrophages have been identified as key regulators of electrical conduction in the AV node. 
It has been demonstrated that resident macrophages are enriched in the AV node, are 
electrically coupled to cardiomyocytes via connexin-43, and alter the electrophysiologic 
properties of coupled cardiomyocytes by increasing the resting membrane potential and 
shortening the action potential duration which facilitates electrical conduction. 
The results of this Habilitation helped to increase our knowledge on proarrhythmic 
remodeling but several challenges remain. Some of the investigations were carried out on 
human samples and are thus highly valuable but provide rather indirect results and remain 
descriptive in most cases. Furthermore, human biosamples, especially heart tissue is very 
limited and even if available only some experiments are possible (e.g. expression analysis) 
while others are technically highly challenging (e.g. isolation of cells for patch clamp studies) 
or even impossible (e.g. genetic manipulation). To study causal arrhythmia mechanisms 
animal models are necessary and some of the findings presented here have been acquired in 
animals. The majority of basic science findings have been obtained in mouse models, these 
findings, however, cannot be directly applied to patients but require validation in animal 
models that closely resemble the human disease. This so-called translation of basic science 
findings into clinical practice will be the biggest challenge for researchers in the future. 
Every animal species used in arrhythmia research has some specific advantages and 
disadvantages96, 97. However, the pig seems to be the most suitable species for most studies 
for several reasons: i) the porcine cardiac anatomy, hemodynamic properties, and 
electrophysiology closely resembles the human situation (Fig.14); ii) instrumentation in pigs is 
relatively simple as human equipment can be used; iii) pigs are widely available and their use 
for research purposes is socially more accepted compared to other species such as dogs; and 
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iv) genetic engineering is available resulting in a growing number of genetically modified pigs 
(e.g. pigs with neonatal diabetes mellitus). These characteristics will allow to generate 




Recently, we have demonstrated the translational potential of pigs for arrhythmia research98. 
In clinical practice, the most common trigger for AF is myocardial ischemia. Thus, we induced 
a myocardial infarction by ballon occlusion of the LAD for 90 minutes inducing an ischemic 




Ejection fraction was significantly reduced and the left ventricular end-diastolic pressure was 
significantly elevated which caused an increase in both left and right atrial pressure and finally 
the development of atrial fibrosis (Fig.15E-F). This structural remodeling finally resulted in an 
enhanced susceptibility for induced AF, longer AF episodes, and an increased AF burden in 
pigs with ischemic heart failure (Fig.15A-D). In sum, we could demonstrate that myocardial 
ischemia induces a proarrhythmic atrial remodeling leading to AF and could confirm the pig as 
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